These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15800336)

  • 1. Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.
    Chim CS; Ooi GC; Loong F; Au AW; Lie AK
    J Clin Oncol; 2005 Apr; 23(10):2426-8. PubMed ID: 15800336
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
    Ali R; Ozkalemkas F; Ozkan A; Ozkocaman V; Ozcelik T; Ozan U; Kurt M; Tunali A
    Leuk Res; 2007 Aug; 31(8):1153-5. PubMed ID: 16945413
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib therapy following first relapse.
    Orlowski RZ;
    Oncology (Williston Park); 2005 Jan; 19(1):23-6. PubMed ID: 15743149
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
    Wei JY; Tong HY; Zhu WF; Liu H; Zhang FJ; Yu WJ; Jin J
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):329-31. PubMed ID: 19502179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
    Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
    Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical analysis of bortezomib combined with chemotherapy for one case of refractory acute lymphocytic leukemia].
    Xu JJ; Hu XH; Shen YY
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):697-8. PubMed ID: 22339831
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas.
    Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Lazzarino M; Corso A
    Leuk Res; 2008 May; 32(5):839-41. PubMed ID: 17997154
    [No Abstract]   [Full Text] [Related]  

  • 8. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
    Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
    Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.
    Krauth MT; Bankier A; Valent P; Kalhs P; Drach J
    Leuk Res; 2005 Dec; 29(12):1473-7. PubMed ID: 15964068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
    Richardson P
    Oncology (Williston Park); 2006 May; 20(6):633-8. PubMed ID: 16773847
    [No Abstract]   [Full Text] [Related]  

  • 11. First report of a medullar cord compression secondary to osseous plasmacytoma successfully treated with bortezomib and dexamethasone.
    Español I; Martínez A; López MD; Iturbe T; Tejedor A; García MC; Cavero S; Funes C; Ibáñez J
    Leuk Res; 2010 Apr; 34(4):e97-9. PubMed ID: 19836836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
    Sharman JP; Chmielecki J; Morosini D; Palmer GA; Ross JS; Stephens PJ; Stafl J; Miller VA; Ali SM
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e161-3. PubMed ID: 24997557
    [No Abstract]   [Full Text] [Related]  

  • 13. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR; Jagannath S; Barlogie B; Siegel DT; Alexanian R; Richardson PG; Irwin D; Alsina M; Rajkumar SV; Srkalovic G; Singhal S; Limentani S; Niesvizky R; Esseltine DL; Trehu E; Schenkein DP; Anderson K
    Cancer; 2005 Nov; 104(10):2141-8. PubMed ID: 16206291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
    Fisher RI; Bernstein SH; Kahl BS; Djulbegovic B; Robertson MJ; de Vos S; Epner E; Krishnan A; Leonard JP; Lonial S; Stadtmauer EA; O'Connor OA; Shi H; Boral AL; Goy A
    J Clin Oncol; 2006 Oct; 24(30):4867-74. PubMed ID: 17001068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
    Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
    Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
    [No Abstract]   [Full Text] [Related]  

  • 18. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
    Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
    Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
    [No Abstract]   [Full Text] [Related]  

  • 19. Incorporating bortezomib into the treatment of lung cancer.
    Davies AM; Lara PN; Mack PC; Gandara DR
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4647-51. PubMed ID: 17671158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of extramedullary gastric plasmacytoma with the combination of bortezomib and dexamethasone: first reported case.
    Katodritou E; Kartsios C; Gastari V; Verrou E; Mihou D; Banti A; Lazaraki G; Lazaridou A; Kaloutsi V; Zervas K
    Leuk Res; 2008 Feb; 32(2):339-41. PubMed ID: 17560647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.